In vitro cytotoxicity of 131I-Rituximab against B-cell lymphoma cells.
- Author:
Li WEI
1
;
Rong-cheng LUO
;
Jun-yi ZHANG
;
Xiao YAN
;
Cheng-wei LÜ
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal; pharmacology; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; immunology; Apoptosis; drug effects; Dose-Response Relationship, Drug; Humans; Iodine Radioisotopes; pharmacology; Lymphoma, B-Cell; pathology; Radioimmunotherapy; Tumor Cells, Cultured
- From: Journal of Southern Medical University 2009;29(1):40-43
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the specific cytotoxicity of (131)I-Rituximab against CD20-positive B-cell lymphoma cells.
METHODSRituximab was labeled with (131)I using IODO-GEN method, and the dose-effects of various concentrations of (131)I-Rituximab, (131)I alone and Rituximab in Raji cells were evaluated by MTT assay to determine the optimal dose according to the dose-effect curves. The cytotoxicity of (131)I-Rituximab, (131)I and Rituximab was assessed in CD20-positive Ramos (RA-1) cells, Raji cells and CD20-negative Molt-4 cells according to the changes of the survival rates. Giemsa staining was used to evaluate the antitumor effect of (131)I-Rituximab in Raji cells by measuring the mitosis index (MI).
RESULTS(131)I-Rituximab presented with a dose-dependent cytotoxicity against Raji cells. At the specific activity of 60 microCi/ml, (131)I-Rituximab resulted in significantly higher growth inhibition rate of the cells than Rituximab (P<0.05). The inhibition rate of Raji cells treated with (131)I-Rituximab, (131)I, or Rituximab for 96 h were comparable with the rates in Ramos RA-1 cells, but significantly higher than the rates in Molt-4 cells. The MI values in (131)I-Rituximab group were significantly lower than those in the other groups (P<0.001).
CONCLUSION(131)I-Rituximab can induce specific cytotoxicity against CD20-positive tumor cells, and may potentially serve as an agent for targeted radioimmunotherapy for CD20-positive B-cell lymphoma.
